Spots Global Cancer Trial Database for chimeric antigen receptor t cells
Every month we try and update this database with for chimeric antigen receptor t cells cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS | NCT03291444 | Leukemia, Acute... Leukemia, Acute... Myelodysplastic... | Chimeric antige... peptide specifi... | 18 Years - 80 Years | Zhujiang Hospital | |
| A Single-center Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-L10D Cell Formulations Targeting CD19 and CD22 in Patients With CD19- and/or CD22-Positive Relapsed/Refractory B-cell Lymphoma | NCT03593109 | Lymphoma, B-Cel... | Dual Specificit... | 18 Years - 75 Years | Second Affiliated Hospital of Xi'an Jiaotong University | |
| Relmacabtagene Autoleucel in Patients With LBCL | NCT06142175 | Large B-cell Ly... | Relmacabtagene ... | 18 Years - | Shanghai Ming Ju Biotechnology Co., Ltd. | |
| Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in R/R Acute B Lymphoblastic Leukemia | NCT04094766 | Refractory B Ac... Relapse B Acute... | Dual Specificit... | 14 Years - 60 Years | Second Affiliated Hospital of Xi'an Jiaotong University | |
| Relmacabtagene Autoleucel as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL | NCT06093841 | Lymphoma, Large... Follicular Lymp... High-grade B-ce... Mediastinal B-C... | Relmacabtagene ... Fludarabine Cyclophosphamid... | 18 Years - | Shanghai Ming Ju Biotechnology Co., Ltd. | |
| CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS | NCT03291444 | Leukemia, Acute... Leukemia, Acute... Myelodysplastic... | Chimeric antige... peptide specifi... | 18 Years - 80 Years | Zhujiang Hospital | |
| AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma | NCT03434769 | Non-Hodgkin Lym... | Cyclophosphamid... Fludarabine CAR-T Cells | 18 Years - | Case Comprehensive Cancer Center | |
| CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS | NCT03291444 | Leukemia, Acute... Leukemia, Acute... Myelodysplastic... | Chimeric antige... peptide specifi... | 18 Years - 80 Years | Zhujiang Hospital | |
| Relmacabtagene Autoleucel in Hematologic Malignancies | NCT06142188 | Lymphoma, B-Cel... Large B-cell Ly... Follicular Lymp... | Relmacabtagene ... | 18 Years - | Shanghai Ming Ju Biotechnology Co., Ltd. | |
| XLCART001 Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects | NCT03598179 | Lymphoma, B-Cel... Leukemia, B-cel... | chimeric antige... | 18 Years - | The First Affiliated Hospital with Nanjing Medical University | |
| Personalized Chimeric Antigen Receptor T Cell Immunotherapy for Patients With Recurrent Malignant Gliomas | NCT03423992 | Glioma Malignant Gliom... Recurrence Tumo... | chimeric antige... | 18 Years - 70 Years | Xuanwu Hospital, Beijing | |
| CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies | NCT03765177 | Acute Lymphobla... Non-Hodgkin's L... Chronic Lymphoc... | CLIC-1901 | 18 Years - 75 Years | Ottawa Hospital Research Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
